Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:NTRP

Neurotrope (NTRP) Stock Price, News & Analysis

Neurotrope logo

About Neurotrope Stock (NASDAQ:NTRP)

Key Stats

Today's Range
$1.46
$1.92
50-Day Range
$0.92
$1.05
52-Week Range
$0.68
$3.85
Volume
31,095 shs
Average Volume
32,512 shs
Market Capitalization
$2.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.

Receive NTRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurotrope and its competitors with MarketBeat's FREE daily newsletter.

NTRP Stock News Headlines

JD Vance Predicts: Wall Street vs. Trump & Your Money
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
NextTrip Inc NTRP
See More Headlines

NTRP Stock Analysis - Frequently Asked Questions

Neurotrope, Inc. (NASDAQ:NTRP) issued its quarterly earnings results on Tuesday, October, 30th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.05.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neurotrope investors own include Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS), Fibrocell Science (FCSC), Bristol-Myers Squibb (BMY), Intel (INTC), Meta Platforms (META) and Pfizer (PFE).

Company Calendar

Last Earnings
10/30/2018
Today
11/24/2024
Next Earnings (Estimated)
1/21/2025
Fiscal Year End
2/28/2025

Industry, Sector and Symbol

Industry
Transportation services
Sub-Industry
N/A
Current Symbol
NASDAQ:NTRP
Employees
5
Year Founded
N/A

Profitability

Pretax Margin
-904.14%

Debt

Sales & Book Value

Annual Sales
$630,000.00
Book Value
$3.34 per share

Miscellaneous

Free Float
1,283,000
Market Cap
$2.50 million
Optionable
No Data
Beta
1.67
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:NTRP) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners